BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO)
· seekingalpha.com
BridgeBio Pharma, Inc. stays a Buy as Attruby launches and the late-stage rare disease pipeline advances. Click for this BBIO stock update.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and ...